Efficacy Advantages of TNF-Alpha Inhibitors Will Likely Constrain Uptake of Emerging Therapies, According to a New Report from Decision Resources
June 3, 2013—Burlington, Mass. —Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that based on clinical data and the opinions of interviewed thought leaders, AbbVie/Eisai’s Humira has the strongest clinical profile among key marketed products that treat psoriatic arthritis (PsA). None of the PsA therapies in development show advantages in efficacy over Humira, although UCB/Astellas’s Cimzia has a clinical profile that is not differentiated from Humira based on thought leader opinion and clinical trial data.
According to the DecisionBase 2013 report entitled Opportunity Remains for Novel Therapies That Address Rheumatologists’ and Payers’ Shared Views on Unmet Need in the TNF-Alpha-Inhibitor-Dominated PsA Market, while some other therapies in development hold promise, they have efficacy, safety and tolerability, and/or delivery disadvantages compared with Humira and Cimzia.
“The TNF-alpha inhibitors have set a high clinical standard that is challenging for emerging therapies to surpass,” said Decision Resources Senior Analyst Bingnan Kang, Ph.D. “However, unmet needs exist for improvements in various efficacy, safety and tolerability, and delivery attributes. The PsA pipeline contains several agents with novel mechanisms of action that have the potential to fulfill some of these unmet needs.”
The report also finds that physicians in the U.S. and Europe and managed care organization (MCO) pharmacy directors in the U.S. identify the need for new therapies with greater ability to halt progression of structural damage as a key unmet need. In addition, surveyed U.S. MCO pharmacy directors are particularly receptive to new PsA therapies that offer improved effect on signs and symptoms of arthritis over currently available therapies. Improvement of signs and symptoms and inhibition of progression of structural damage are two key treatment goals in the management of PsA.
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.